Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Bronchial Asthma | Research

Estimating loss in quality of life associated with asthma-related crisis events (ESQUARE): a cohort, observational study

Authors: Christina-Jane Crossman-Barnes, Tracey Sach, Andrew Wilson, Garry Barton

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

Evidence of quality of life implications of asthma attacks are limited, particularly when measured on a utility scale, which enables calculating Quality-Adjusted Life-Years (QALYs) and comparisons with other health conditions and services. Therefore, this study sought to estimate the utility loss associated with an asthma-related crisis event (accident and emergency (A&E) attendance or hospital admission).

Methods

Participants were recruited in a cohort study from A&E and hospital admissions at three UK hospitals. They completed the EuroQol-5 Dimensions 5-Level (EQ-5D-5 L), Asthma Quality of Life Questionnaire (AQLQ), Time trade-off (TTO), and peak flow and symptom diary over 8 weeks, where three different methods (EQ-5D-5 L, AQLQ, and TTO), were used to estimate utilities. The mean difference between two time points were estimated using the Wilcoxon signed rank test.

Results

From baseline to week 8, mean increases (95% CI) were estimated to be 0.086 (0.019–0.153), 0.154 (0.112–0.196) and 0.132 (0.063–0.201) for EQ-5D-5 L, AQL-5D (preference-based measure derived from AQLQ), and TTO respectively over 8 weeks (p < 0.01).

Conclusion

Asthma crisis events are estimated to be associated with a mean utility loss of between 0.086 and 0.132. The utility decrement can be used to assign values to asthma-related crisis events, which can enhance economic evaluations.

Trial registration

NCT02771678. Registered 13 May 2016.
Appendix
Available only for authorised users
Literature
1.
go back to reference British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: A national clinical guideline 2016. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: A national clinical guideline 2016.
3.
go back to reference Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M, Fitzsimmons D, Bandyopadhyay A, Aftab C, Simpson CR, Lyons RA, Fischbacher C, Dibben C, Shields MD, Phillips CJ, Strachan DP, Davies GA, McKinstry B, Sheikh A. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med. 2016;14(1):113.CrossRef Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M, Fitzsimmons D, Bandyopadhyay A, Aftab C, Simpson CR, Lyons RA, Fischbacher C, Dibben C, Shields MD, Phillips CJ, Strachan DP, Davies GA, McKinstry B, Sheikh A. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med. 2016;14(1):113.CrossRef
4.
go back to reference Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, Hahn RM, Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48(2):126–32.CrossRef Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, Hahn RM, Schatz M. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48(2):126–32.CrossRef
5.
go back to reference Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, Pertega-Diaz S, Verea-Hernando H. Utility of brief questionnaires of health-related quality of life (airways questionnaire 20 and clinical COPD questionnaire) to predict exacerbations in patients with asthma and COPD. Health Qual Life Outcomes. 2013;11:85.CrossRef Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, Pertega-Diaz S, Verea-Hernando H. Utility of brief questionnaires of health-related quality of life (airways questionnaire 20 and clinical COPD questionnaire) to predict exacerbations in patients with asthma and COPD. Health Qual Life Outcomes. 2013;11:85.CrossRef
6.
go back to reference Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544–52 e1–2.CrossRef Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544–52 e1–2.CrossRef
7.
go back to reference Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff Resour Alloc. 2007;5:10.CrossRef Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff Resour Alloc. 2007;5:10.CrossRef
8.
go back to reference Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams HC. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS One. 2014;9(2):e82694.CrossRef Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams HC. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS One. 2014;9(2):e82694.CrossRef
9.
go back to reference Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making. 2007;27(4):414–22.CrossRef Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making. 2007;27(4):414–22.CrossRef
10.
go back to reference Jakovljević MB, Tetsuji Y, Chia Ching C, Stevanovic DS, Jovanovic MR, Nikić Djuričić KD, Rančić NK, Savić DM, Biorac NM, Mihajlovic GS, Jankovic SM. Cost-effectiveness of depressive episode pharmacological treatment. Hospital Pharmacology. 2015;2(1):235–45. Jakovljević MB, Tetsuji Y, Chia Ching C, Stevanovic DS, Jovanovic MR, Nikić Djuričić KD, Rančić NK, Savić DM, Biorac NM, Mihajlovic GS, Jankovic SM. Cost-effectiveness of depressive episode pharmacological treatment. Hospital Pharmacology. 2015;2(1):235–45.
11.
go back to reference Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.CrossRef Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health Qual Life Outcomes. 2018;16(1):31.CrossRef
12.
go back to reference Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRef Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRef
13.
go back to reference Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRef Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRef
14.
go back to reference Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Health Qual Life Outcomes. 2015;13:106.CrossRef Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Health Qual Life Outcomes. 2015;13:106.CrossRef
15.
go back to reference Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19(1–2):227–33.CrossRef Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs. 2010;19(1–2):227–33.CrossRef
16.
go back to reference Perez DJ, McGee R, Campbell AV, Christensen EA, Williams S. A comparison of time trade-off and quality of life measures in patients with advanced cancer. Qual Life Res. 1997;6(2):133–8.CrossRef Perez DJ, McGee R, Campbell AV, Christensen EA, Williams S. A comparison of time trade-off and quality of life measures in patients with advanced cancer. Qual Life Res. 1997;6(2):133–8.CrossRef
17.
go back to reference Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, Thomson R, Paleri V, Wilson JA. Quality compared to quantity of life in laryngeal cancer: a time trade-off study. Head & neck. 2015;38(S1):631–37. Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, Thomson R, Paleri V, Wilson JA. Quality compared to quantity of life in laryngeal cancer: a time trade-off study. Head & neck. 2015;38(S1):631–37.
18.
go back to reference Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol. 1995;48(10):1207–14.CrossRef Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol. 1995;48(10):1207–14.CrossRef
19.
go back to reference van Reenen M, Janssen B. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument; 2015. van Reenen M, Janssen B. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument; 2015.
20.
go back to reference Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.CrossRef Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.CrossRef
21.
go back to reference Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ. 1996;5(2):141–54.CrossRef Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ. 1996;5(2):141–54.CrossRef
22.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care Programmes. 4th ed. New York: Oxford University Press; 2015. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care Programmes. 4th ed. New York: Oxford University Press; 2015.
24.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRef Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRef
25.
go back to reference Devlin N, Shah K, Feng Y, Brendan M, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England: research paper 16/01. London: Office of Health Economics; 2016. Devlin N, Shah K, Feng Y, Brendan M, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England: research paper 16/01. London: Office of Health Economics; 2016.
26.
go back to reference Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making. 2011;31(1):195–210.CrossRef Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making. 2011;31(1):195–210.CrossRef
27.
go back to reference Shah K, Mulhern B, Longworth L, Janssen MF. An empirical study of two alternative comparators for use in time trade-off studies. Value Health. 2016;19(1):53–9.CrossRef Shah K, Mulhern B, Longworth L, Janssen MF. An empirical study of two alternative comparators for use in time trade-off studies. Value Health. 2016;19(1):53–9.CrossRef
29.
go back to reference Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M. Control of asthma in real life: still a valuable goal? Eur Respir Rev. 2015;24(136):361–9.CrossRef Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M. Control of asthma in real life: still a valuable goal? Eur Respir Rev. 2015;24(136):361–9.CrossRef
30.
go back to reference Pearson MG, Bucknall CE. Measuring clinical outcome in asthma: a patient-focused approach. London: Royal College of Physicians; 1999. Pearson MG, Bucknall CE. Measuring clinical outcome in asthma: a patient-focused approach. London: Royal College of Physicians; 1999.
32.
go back to reference Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–7.CrossRef Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–7.CrossRef
33.
go back to reference Sturdy PM, Butland BK, Anderson HR, Ayres JG, Bland JM, Harrison BD, Peckitt C, Victor CR. National Asthma Campaign M, severe morbidity G. Deaths certified as asthma and use of medical services: a national case-control study. Thorax. 2005;60(11):909–15.CrossRef Sturdy PM, Butland BK, Anderson HR, Ayres JG, Bland JM, Harrison BD, Peckitt C, Victor CR. National Asthma Campaign M, severe morbidity G. Deaths certified as asthma and use of medical services: a national case-control study. Thorax. 2005;60(11):909–15.CrossRef
34.
go back to reference Attema AE, Brouwer WB. The value of correcting values: influence and importance of correcting TTO scores for time preference. Value Health. 2010;13(8):879–84.CrossRef Attema AE, Brouwer WB. The value of correcting values: influence and importance of correcting TTO scores for time preference. Value Health. 2010;13(8):879–84.CrossRef
35.
go back to reference Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. PharmacoEconomics. 2018;36(7):745–58.CrossRef Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. PharmacoEconomics. 2018;36(7):745–58.CrossRef
36.
go back to reference Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, Meads D, O'Dwyer J, Barton G, Irvine L. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRef Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, Meads D, O'Dwyer J, Barton G, Irvine L. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRef
37.
go back to reference Sayah FA, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie F, Johnson JA. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Qual Life Res. 2016;25(7):1679–85.CrossRef Sayah FA, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie F, Johnson JA. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Qual Life Res. 2016;25(7):1679–85.CrossRef
38.
go back to reference Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis: time out for time tradeoff. Med Humanit. 2003;29(2):81–6.CrossRef Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis: time out for time tradeoff. Med Humanit. 2003;29(2):81–6.CrossRef
39.
go back to reference Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, Windley J, Holland R, Harrison BD, Howe A, Price DB, Harvey I, Wilson AM. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax. 2012;67(12):1052–60.CrossRef Smith JR, Noble MJ, Musgrave S, Murdoch J, Price GM, Barton GR, Windley J, Holland R, Harrison BD, Howe A, Price DB, Harvey I, Wilson AM. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax. 2012;67(12):1052–60.CrossRef
40.
go back to reference NICE. Guide to the methods of technology appraisal. 2013:2013. NICE. Guide to the methods of technology appraisal. 2013:2013.
Metadata
Title
Estimating loss in quality of life associated with asthma-related crisis events (ESQUARE): a cohort, observational study
Authors
Christina-Jane Crossman-Barnes
Tracey Sach
Andrew Wilson
Garry Barton
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1138-5

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue